Isomorphic Labs Strikes Multi-Billion Dollar Deals with Eli Lilly and Novartis


In a significant move within the pharmaceutical industry, Isomorphic Labs, a subsidiary of tech giant Alphabet Inc., has announced strategic research collaborations with two of the world’s leading pharmaceutical companies, Eli Lilly and Company and Novartis AG. These partnerships, focusing on the discovery of small molecule therapeutics, are poised to potentially bring nearly $3 billion to Isomorphic Labs, not including future royalties from drug sales.

Isomorphic Labs: A Forerunner in AI-Driven Drug Discovery

Isomorphic Labs, leveraging the groundbreaking AlphaFold AI technology developed by Google’s DeepMind, has been at the forefront of integrating artificial intelligence into the drug discovery process. The company’s platform aims to accelerate the identification of drug targets and the design of new compounds, potentially revolutionizing how medications are developed.

Strategic Collaborations with Eli Lilly and Novartis

The collaboration with Eli Lilly involves an upfront payment of $45 million to Isomorphic Labs, with the possibility of $1.7 billion in milestone payments, plus tiered royalties on net sales. The partnership will focus on multiple disease targets, although specific diseases have not been disclosed.

FILE PHOTO: The company’s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo

Similarly, the deal with Novartis includes an upfront cash infusion of $37.5 million, with Novartis also covering some research costs. Isomorphic Labs could receive up to $1.2 billion in milestone payments from this collaboration, which targets three undisclosed disease areas

FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar

Financial Implications and Market Response

The announcement of these deals has had a noticeable impact on the stock market, with Eli Lilly’s stock jumping 6.1% and Novartis’s stock rising 5.3% following the news. The collaborations are seen as a validation of Isomorphic Labs’ AI-driven approach to drug discovery and have generated excitement within the industry.

Future Prospects

These partnerships mark a significant milestone for Isomorphic Labs, which has been relatively quiet since its inception within Alphabet. With a scientific advisory board that includes Nobel Prize winners and a focus on cutting-edge AI models, Isomorphic Labs is well-positioned to make substantial contributions to the field of drug discovery

The collaborations with Eli Lilly and Novartis are multi-target, with both upfront and milestone payments, reflecting the potential of Isomorphic Labs’ technology to create value for its partners and improve the drug discovery process. As the company continues to develop and apply its AI platform, the pharmaceutical industry watches closely for the next breakthroughs that may emerge from this strategic alliance.

Chinonso Anyaehie

Chinonso Anyaehie

Chinonso Anyaehie is a leading voice exploring the societal impacts of artificial intelligence and emerging technologies. As founder of the popular technology blog DecentraPress, Chinonso Anyaehie complex innovations like blockchain, robotics, and AI, transforming dense research into accessible, engaging stories.

With over 7 years of experience as a science and tech writer, Chinonso Anyaehie provides thoughtful analysis on how bleeding-edge breakthroughs are reshaping our world. He delves into the progress and pitfalls of exponential technologies through an accessible, human-centric lens.

In addition to running DecentraPress, Chinonso Anyaehie is a frequent contributor to major tech publications and conferences. He is committed to fostering nuanced conversations on how we ethically steer emerging advances for the benefit of humanity.

Leave a Reply

Your email address will not be published. Required fields are marked *